KRAS and non-small cell lung carcinoma: Yet, the differences in the TME/TIME between EGFR- and KRAS-mutant tumors, as well as their mutational subtypes, underscore the challenge of developing a one-size-fits-all immunotherapy approach for the genetic subtypes of NSCLC.